Chronic mucocutaneous candidiasis, pancytopenia, and systemic mycosis in a patient with STAT1 gene mutation ineffectively treated with ruxolitinib

STANISŁAWA BAZAN-SOCHA¹, ADA GRADZIKIEWICZ², MAGDALENA CELIŃSKA-LOWENHOFF³, ALEKSANDRA MATYJA-BEDNARCZYK⁴, ANNA MACIOŁEK⁵, KATARZYNA BĄBOL-POKORA⁶

¹Department of Internal Medicine, Jagiellonian University Medical College, Cracow, Poland
²Department of Metabolic Diseases and Diabetology, Jagiellonian University Medical College, Cracow, Poland
³Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Łódź, Poland

We present a case of a white adult female patient who suffered from chronic mucocutaneous candidiasis (CMC) since infancy. Her parents were not consanguineous, and neither of them nor any other family member, including an older sister, suffered from similar symptoms. The patient often received prolonged courses of antifungal antibiotics, but the regimens were always insufficiently effective. The differential diagnosis included atopic dermatitis or acrodermatitis enteropathica, a rare, usually genetic disorder of zinc metabolism characterized by pustular dermatitis, diarrhea, and nail dystrophy. At the age of 18, the patient was diagnosed with type 1 diabetes mellitus. Five years later, human immunoglobulin substitution was started due to immunoglobulin (Ig) G2 and IgG4 mild deficiency.

At the age of 35, during voriconazole therapy, the patient’s clinical state became complicated with severe pancytopenia and invasive candidiasis. She was febrile; laboratory tests revealed neutropenia (1,560/μl), lymphopenia (300/μl), thrombocytopenia (22,000/μl), and mild anemia (hemoglobin 10.1 g/dl). Microbiological swabs of mucosal and skin lesions (Fig. 1) demonstrated massive growth of Candida albicans and Staphylococcus aureus. Abdominal computed tomography depicted spleen changes, radiologically corresponding to invasive candidiasis (Fig. 1). The patient was treated with liposomal amphotericin and broad-spectrum antibiotics, followed by posaconazole and filgrastim. However, the clinical condition did not improve. Bone marrow biopsy revealed hypocellular smear with severe granulocytic and red blood cell line hypoplasia, atypical megakaryoblast with disturbed platelet formation, single, small CD20⁺ B cells, and numerous CD3⁺ T cells in disseminated and clumping form, without evidence of any neoplastic disorder. The immunosuppressive regimen with intravenous methylprednisolone and immunoglobulins was applied due to suspicion of autoimmune T cell dysregulation or drug-induced (azoles) pancytopenia, with tremendous clinical and laboratory improvement.

Immunological investigations demonstrated lymphopenia predominantly with absence of circulating B cells and a low number of natural killer cells. Serum immunoglobulins, including IgG subclasses, were in the normal range, mitogen stimulation of lymphocyte culture was normal, while antigen stimulation was ineffective. Chronic granulomatosis disease and interferon γ/interleukin 12 axis disturbance were excluded. Next generation sequencing using the NextSeq 350 Sequencing System (Illumina, San Diego CA, USA) with a custom-designed Sure Select QXT Panel (Agilent, Santa Clara CA, USA), comprising 652 genes related to hematological diseases and bioinformatics tools, such as Mutation Taster [1] and PolyPhen [2], documented a de novo heterogeneous pathogenic variant in the DNA-binding domain of the signal transducer and activator of transcription 1 (STAT1) gene, which was confirmed by Sanger sequencing. Both parents were also tested, but they were negative for the mutation. That missense c.1170 G>A change refers to the methionine to isoleucine substitution in the 390 position of the STAT1 protein chain (p.Met390Ile) and according to the predictive software is related to the dominant mode of the STAT1 protein. Immunological investigations demonstrated lymphopenia predominantly with absence of circulating B cells and a low number of natural killer cells. Serum immunoglobulins, including IgG subclasses, were in the normal range, mitogen stimulation of lymphocyte culture was normal, while antigen stimulation was ineffective. Chronic granulomatosis disease and interferon γ/interleukin 12 axis disturbance were excluded. Next generation sequencing using the NextSeq 350 Sequencing System (Illumina, San Diego CA, USA) with a custom-designed Sure Select QXT Panel (Agilent, Santa Clara CA, USA), comprising 652 genes related to hematological diseases and bioinformatics tools, such as Mutation Taster [1] and PolyPhen [2], documented a de novo heterogeneous pathogenic variant in the DNA-binding domain of the signal transducer and activator of transcription 1 (STAT1) gene, which was confirmed by Sanger sequencing. Both parents were also tested, but they were negative for the mutation. That missense c.1170 G>A change refers to the methionine to isoleucine substitution in the 390 position of the STAT1 protein chain (p.Met390Ile) and according to the predictive software is related to the dominant mode of the primary immunodeficiency with CMC (IMD31C), Online Mendelian Inheritance in Man (OMIM), number sign 614162. The revealed gain of function (GOF) mutation was previously described in a 4-year-old Algerian boy and a 10-year-old boy from Hong Kong with a classical CMC phenotype [3, 4]. Furthermore, a genetic test revealed a homozygous variant of unknown significance in the NCF1 gene, referred to as the substitution of arginine to histidine in position 90 of the protein chain. Mutation in that gene might be associated with the chronic granuloma-
Chronic mucocutaneous candidiasis, pancytopenia, and systemic mycosis in a patient with STAT1 gene mutation ineffectively treated with ruxolitinib

tous disease; however, Phagoburst and nitroblue tetrazolium tests were normal in our patient; thus, we considered the described variant as clinically irrelevant.

Based on the literature data, the patient was administered ruxolitinib, a Janus kinase (JAK) 1 and JAK2 inhibitor, recently shown as effective in patients with STAT1 GOF mutation [5-10]. However, six months of therapy with that medication in a dose of 10 mg twice a day was not related to a clinically significant improvement, i.e., skin and mucosal changes were still severe, and pancytopenia persisted.

In addition, the patient required regular filgrastim application and frequent red blood cell and platelet transfusion. Therefore, ruxolitinib was discontinued. The follow-up bone marrow biopsy again showed a hypocellular smear with pathological changes corresponding to bone marrow aplasia. Consequently, the diagnosis of aplastic anemia was made, likely related to T-cell dysregulation. The presence of chronic fungal and bacterial skin and mucosal lesions disqualified the patient from bone marrow transplantation, and three months later, she died from sepsis.

Fig. 1. Mucous, skin, and nail candidiasis. Abdominal computed tomography with invasive spleen mycosis
In 2016 Toubiana et al. [4] described a large cohort of 274 patients from 40 countries with various autosomal dominant heterozygous STAT1 GOF mutations. Almost all those individuals presented CMC, with a median age at onset of 1 year. Bacterial infections, mainly by Staphylococcus aureus, as well as viral and mycobacterial, were also frequent. Furthermore, many patients had autoimmune manifestations, including type 1 diabetes, autoimmune cytopenias, and aplastic anemia, as observed in our patient. Invasive candidiasis, intracranial aneurysms, and cancers were predictors of poor outcomes [4].

In the pathogenesis of CMC, enhanced STAT1 activation is related to increased JAK signaling [5, 11]. Therefore, in that disorder, ruxolitinib has been previously reported to treat alopecia, fungal infections, thrush, autoimmune cytopenias, and even diabetes, albeit with varied clinical responses [5-10]. However, we did not find any data on its application in aplastic anemia complicating CMC. Rosenberg et al. [11] recently described an 18-year-old man with aplastic anemia and STAT1 GOF mutation, who was successfully treated with itacitinib, a new, investigational JAK1 inhibitor. That medication resulted in the prompt recovery of hematopoiesis. Therefore, it might be a therapeutic option in bone marrow lesions related to CMC and other autoimmune or immunodeficiency cases.

Conclusions

We present this case to increase CMC awareness and as a reminder that it is an immune disease, not only a dermatologic one. It may refer to the STAT1 GOF gene pathological variant, or it may be de novo with no familiar history, like in our case. This disease also requires a specific type of treatment, such as JAK inhibitors and not only antifungal medications. However, choosing appropriate medication requires further experimental and clinical studies since ruxolitinib was ineffective in our case. We may only speculate that its earlier administration, i.e., before the severe bone marrow lesion, would be more efficient. In addition, in some severe CMC complications, such as aplastic anemia, itacitinib, a new selective JAK1 inhibitor, may raise some hopes. Since itacitinib does not block JAK2, erythropoietin and thrombopoietin receptors downstream, it may be more effective in hematologic disorders related to autoimmune diseases or immunodeficiencies.

The authors declare no conflict of interest.

References

1. Schwarz J, Cooper D, Schuelke M, et al. (2014): Mutation-Taster2: mutation prediction for the deep-sequencing age. Nat Methods 11: 361-362.
2. Adzhubei IA, Schmidt S, Peshkin L, et al. (2010): A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
3. Lee PP, Lao-Araya M, Yang J, et al. (2019): Application of flow cytometry in the diagnostics pipeline of primary immunodeficiencies underlying disseminated Talaromyces marneffei infection in HIV-negative children. Front Immunol 10: 1-13.
4. Toubiana J, Okada S, Hiller J, et al. (2016): Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. Blood 127: 3154-3164.
5. Moriya K, Suzuki T, Uchida N, et al. (2020): Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation. Int J Hematol 112: 258-262.
6. Weinacht KG, Charbonnier LM, Alroqi F, et al. (2017): Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol 139: 1629-1640.e2.
7. Bloomfield M, Kanderová V, Paračková Z, et al. (2018): Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol 38: 589-601.
8. Higgins E, Al Shehri T, McAleer MA, et al. (2015): Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. J Allergy Clin Immunol 135: 551-553.
9. Mössner R, Diering N, Bader O, et al. (2016): Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Clin Infectious Diseases 62: 951-953.
10. Chaimowitz NS, Ebenezer SJ, Hanson IC, et al. (2020): STAT1 gain of function, type 1 diabetes, and reversal with JAK inhibition. N Engl J Med 383: 1494-1496.
11. Rosenberg J, Hughes T, Peters J, et al. (2021): An N-of-1 trial of Itacitinib for a patient with aplastic anemia associated with a gain-of-function variant in STAT1, 08 January 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-139401/v1].